期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 74, 期 3, 页码 499-505出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2015.09.061
关键词
angiotensin II; captopril; efficacy; infantile hemangioma; propranolol; side effects; vascular endothelial growth factor
类别
Background: Renin-angiotensin system components have been demonstrated in the biology of infantile hemangioma (IH). Captopril, an angiotensin-converting enzyme inhibitor, is proposed as a therapeutic alternative to oral propranolol. Objectives: We sought to compare the benefit of propranolol and captopril in the treatment of IH, and to assess angiotensin-converting enzyme gene polymorphism in patients with IH and in control subjects. Methods: Thirty patients with IH and 35 healthy control subjects were enrolled in this study. Patients were randomly assigned to treatment with either propranolol or captopril. Assessment was done clinically and by measurement of serum vascular endothelial growth factor and angiotensin II in patients and control subjects. Angiotensin-converting enzyme gene polymorphism was also studied. Results: Clinical improvement was significantly better and faster in the patients treated with propranolol. Both groups showed reduced vascular endothelial growth factor and angiotensin II levels posttreatment, with a significantly higher percentage reduction in the propranolol-treated group. Cardiac side effects were reported only in the captopril-treated group. Baseline vascular endothelial growth factor level was significantly higher, and baseline angiotensin II level was significantly lower, in patients than control subjects. Limitations: We studied a relatively small number of patients and control subjects. Conclusion: Propranolol shows greater benefit than captopril in the treatment of IH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据